臨牀消化器内科 Vol.23 No.6(5-3)


特集名 肝疾患の栄養療法
題名 C型肝炎と栄養療法 (3) C型肝硬変に対する分岐鎖アミノ酸製剤と肝発癌抑制
発刊年月 2008年 06月
著者 小林 正宏 虎の門病院肝臓センター
著者 熊田 博光 虎の門病院肝臓センター
【 要旨 】 分岐鎖アミノ酸 (BCAA) 顆粒は肝硬変患者における低アルブミン血症の改善目的に開発された薬剤であるが,近年C型肝硬変に対する発癌抑制効果が注目されている.C型肝硬変においてはインスリン抵抗性が高頻度に合併し,高インスリン血症が発癌に関与すると考えられている.BCAAは骨格筋における糖の取り込み,グリコーゲン合成を促進し,この結果インスリン抵抗性が改善し,発癌抑制につながると推定される.またわれわれのBCAA顆粒投与群と非投与群のcontrol studyの結果,BCAA顆粒投与後フィッシャー比が3,4以上に上昇した症例においては有意に発癌を含めた肝疾患関連イベントの抑制効果が認められた.
Theme Nutrition Therapy for Liver Diseases
Title Inhibitory Effects of Branched-chain Amino Acids on Hepatocarcinogenesis in Hepatitis C Virus-associated Cirrhosis
Author Masahiro Kobayashi Department of Hepatology, Toranomon Hospital
Author Hiromitsu Kumada Department of Hepatology, Toranomon Hospital
[ Summary ] Branched-chain amino acid (BCAA) granules have been used to reverse hypoalbuminemia in cirrhotic patients. In addition, it is thought that BCAA may decrease the risk of hepatocellular carcinoma (HCC). It is reported that BCAA improves glucose metabolism by promoting glucose uptake and glycogen synthesis in insulin free conditions within skeletal muscle. It is also hypothesized that these improvements in glucose metabolism may be related to anti carcinogenic effects. A randomized control trial for use of BCAA in treating disease progression and development of liver related complications in patients with HCV-related cirrhosis was conducted. Although development rates for liver related complications, including HCC, were not significant in the BCAA treated group or the untreated group, rates were markedly decreased in patients whose Fischer's ratio improved to as high as 3. 4 after administration of BCAA. These results may indicate that utilization of BCAA in skeletal muscle and improvements in Fischer's ratio may be necessary to exhibit anti carcinogenic effects in patients with HCV related cirrhosis.
戻る